Advertisement
Advertisement
Forgram

Forgram

ceftriaxone

Manufacturer:

UNILAB, Inc

Distributor:

UNILAB, Inc
Concise Prescribing Info
Contents
Ceftriaxone Na
Indications/Uses
Treatment of infections of the lower resp tract, acute bacterial otitis media, skin & skin structure infection, UTI, uncomplicated gonorrhea, pelvic inflammatory disease, bacterial septicemia, bone & joint infections, intra-abdominal infections, meningitis.
Dosage/Direction for Use
IM/IV Adult 1-2 g once daily. Max: 4 g daily. Lower resp tract infection 1 g IV 12 or 24 hrly. Uncomplicated gonorrhea 250 mg IM as a single dose. Pelvic inflammatory disease 250 mg IM as a single dose. Surgical prophylaxis 1 g IV as a single dose w/in 2 hr surgery. Orthopedic surgery 2 g IV as a single dose 2 hr pre-op. Meningitis 2 g IV 12 hrly. Infant & childn ≤12 yr Mild to moderate infection 50-75 mg/kg body wt once daily. Max: 2 g daily. Severe infection 100 mg/kg body wt once daily. Max: 4 g daily. Duration of therapy: 4-14 days. Acute otitis media 50 mg/kg body wt IM or IV as a single dose. Max: 1 g. Hepatic & renal impairment Max: 2 g daily.
Contraindications
Hypersensitivity to cephalosporins & penicillins. Hypersensitivity to lidocaine soln (in case of IM inj). Hyperbilirubinemic neonates esp prematures. Concurrent administration w/ Ca-containing soln or products in newborns.
Special Precautions
History of colitis. Hepatic & renal impairment. Monitor prothrombin time. Pregnancy & lactation.
Adverse Reactions
Pain, induration, ecchymosis, tenderness at inj site; rash; eosinophilia, thrombocytosis, leukopenia; diarrhea; elevated AST, ALT & BUN.
Drug Interactions
Probenecid, aminoglycosides, trovafloxacin, alcohol.
MIMS Class
Cephalosporins
ATC Classification
J01DD04 - ceftriaxone ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Presentation/Packing
Form
Forgram powd for inj 1 g
Packing/Price
1's (P995.22/vial)
Form
Forgram powd for inj 500 mg
Packing/Price
(vial) 1's (P566.12/vial)
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement